Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP.
Alcaraz A, et al. Among authors: gonzalez gragera b, gonzalez lopez r, gonzalez enguita c, gonzalez del alba a.
Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25.
Br J Cancer. 2013.
PMID: 23799855
Free PMC article.